{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:12:16Z","timestamp":1792811536072,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","heartandlung.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart &amp; Lung"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.hrtlng.2014.03.004","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T03:27:50Z","timestamp":1399606070000},"page":"262-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state"],"prefix":"10.1016","volume":"43","author":[{"given":"Claudia","family":"St\u00f6llberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Finsterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrtlng.2014.03.004_bib1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"36","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hrtlng.2014.03.004_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000334979","article-title":"New frontiers for stroke prevention in atrial fibrillation","volume":"33","author":"Prasad","year":"2012","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.hrtlng.2014.03.004_bib3","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1177\/1060028013504741","article-title":"Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?","volume":"47","author":"Hellwig","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.hrtlng.2014.03.004_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jcph.5","article-title":"The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban\u2013an oral, direct Factor Xa inhibitor","volume":"53","author":"Kubitza","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.hrtlng.2014.03.004_bib5","doi-asserted-by":"crossref","first-page":"e003343","DOI":"10.1136\/bmjopen-2013-003343","article-title":"Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study","volume":"3","author":"Maccallum","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.hrtlng.2014.03.004_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.amjcard.2013.11.008","article-title":"Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting","volume":"113","author":"Carley","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrtlng.2014.03.004_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-9560-11-10","article-title":"Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring","volume":"11","author":"Mueck","year":"2013","journal-title":"Thromb J"},{"key":"10.1016\/j.hrtlng.2014.03.004_bib8","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.hrtlng.2014.03.004_bib9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1023\/A:1007568811691","article-title":"Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4","volume":"17","author":"Katoh","year":"2000","journal-title":"Pharm Res"},{"issue":"suppl 1","key":"10.1016\/j.hrtlng.2014.03.004_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/(SICI)1520-6394(1998)7:1+<24::AID-DA7>3.0.CO;2-F","article-title":"New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine","volume":"7","author":"Owen","year":"1998","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.hrtlng.2014.03.004_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/MOH.0b013e328365a164","article-title":"Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects","volume":"20","author":"Yates","year":"2013","journal-title":"Curr Opin Hematol"}],"container-title":["Heart &amp; Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956314000739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956314000739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T04:37:42Z","timestamp":1539664662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956314000739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0147956314000739"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2014.03.004","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2014.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}